Imunon (NASDAQ:IMNN) Earns Buy Rating from D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $29.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Imunon in a research note on Thursday, December 19th.

Imunon Price Performance

Imunon stock opened at $0.89 on Thursday. The firm’s fifty day moving average price is $0.90 and its 200 day moving average price is $0.94. The company has a market capitalization of $12.92 million, a price-to-earnings ratio of -0.47 and a beta of 2.03. Imunon has a 12-month low of $0.64 and a 12-month high of $3.65.

Institutional Trading of Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC grew its stake in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the period. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 at the end of the most recent quarter. 4.47% of the stock is currently owned by institutional investors.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.